Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 378.99
-3.74 %
$ 30.7 B
Market Cap
35.52
P/E
1. INTRINSIC VALUE
Balance Sheet
IDEXX Laboratories, Inc.
| Current Assets | 1.4 B |
| Cash & Short-Term Investments | 288 M |
| Receivables | 561 M |
| Other Current Assets | 550 M |
| Non-Current Assets | 1.89 B |
| Long-Term Investments | 57.7 M |
| PP&E | 829 M |
| Other Non-Current Assets | 1.01 B |
| Current Liabilities | 1.07 B |
| Accounts Payable | 114 M |
| Short-Term Debt | 439 M |
| Other Current Liabilities | 514 M |
| Non-Current Liabilities | 630 M |
| Long-Term Debt | 548 M |
| Other Non-Current Liabilities | 82.6 M |
EFFICIENCY
Earnings Waterfall
IDEXX Laboratories, Inc.
| Revenue | 3.9 B |
| Cost Of Revenue | 1.52 B |
| Gross Profit | 2.38 B |
| Operating Expenses | 1.25 B |
| Operating Income | 1.13 B |
| Other Expenses | 240 M |
| Net Income | 888 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
IDEXX Laboratories, Inc.
| Net Income | 888 M |
| Depreciation & Amortization | 130 M |
| Capital Expenditures | -131 M |
| Stock-Based Compensation | 60.3 M |
| Change in Working Capital | -133 M |
| Others | -76.7 M |
| Free Cash Flow | 798 M |
Wall Street Analysts Price Targets
IDEXX Laboratories, Inc.
Wall Street analysts predict an average 1-year price target for IDXX of $501 , with forecasts ranging from
a
low of
$247 to a high of $600 .
IDXX Lowest Price Target
Wall Street Target
247 USD
-34.83%
IDXX Average Price Target
Wall Street Target
501 USD
32.24%
IDXX Highest Price Target
Wall Street Target
600 USD
58.32%
4. DIVIDEND
ANALYSIS
IDXX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
IDEXX Laboratories, Inc.
Sold
0-3 MONTHS
6.02 M USD 2
3-6 MONTHS
145 K USD 1
6-9 MONTHS
235 K USD 1
9-12 MONTHS
108 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
- 1 week ago
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
zacks.com
- 1 week ago
IDEXX Laboratories to Release 2025 First Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website,.
businesswire.com
- 1 week ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
zacks.com
- 1 week ago
Meet the Little-Known S&P 500 Stock That Has Rocketed 10,230% Higher Since 2000
Healthcare diagnostics equipment manufacturer, Idexx Laboratories (IDXX -1.54%), is the global leader in pet care.
fool.com
- 2 weeks ago
Should You Retain IDEXX Stock in Your Portfolio for Now?
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
zacks.com
- 3 weeks ago
IDEXX Laboratories: Cancer Dx Launch In March 2025; Upgrading To 'Buy'
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significant growth and new revenue streams. IDEXX's share repurchase program is robust, with $837 million repurchased in FY24 and a plan for $1.5 billion in FY25.
seekingalpha.com
- 3 weeks ago
IDEXX Laboratories: A Top Dog In The Pet Care Market
The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market leader with a highly profitable business model, operating leverage, and recurring revenues. Once a customer starts using an IDEXX instrument, it is tied to the IDEXX ecosystem.
seekingalpha.com
- 1 month ago
Should You Hold IDEXX Stock in Your Portfolio for Now?
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
zacks.com
- 1 month ago
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March.
businesswire.com
- 1 month ago
IDEXX Laboratories And Its Real Value
IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years.
seekingalpha.com
- 2 months ago
Why Idexx Labs Stock Rocketed Higher This Week
Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.
fool.com
- 2 months ago
8. Profile
Summary
IDEXX Laboratories, Inc. IDXX
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 30.7 B
Dividend Yield
0.00%
Description
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Contact
One IDEXX Drive, Westbrook, ME, 04092
https://www.idexx.com
IPO
Date
June 21, 1991
Employees
11000
Officers
Mr. Brian P. McKeon
Executive Vice President & Special Advisor
Mr. Jonathan J. Mazelsky
President, Chief Executive Officer & Director
Mr. Jeffrey B. Carr
Senior Vice President, GM and Head of Product for Global Reference Labs & IBA